Array’s clinical development strategy is to streamline the drug development process through Phase II clinical trials. We create scientifically robust IND submissions designed to speed initiation of human clinical testing. We have assembled expertise in both clinical development and regulatory affairs through our employees and consultants. Array is building relationships and accessing thought leaders with key academic medical centers for cancer and inflammatory disease, which we believe will facilitate clinical trial design and choice of patient population for our therapeutic products. We also use quantitative, selective measures of biologic activity as related to a drug’s mechanism of action or biomarkers, as an integral element of our clinical design strategy to select patients, predict clinical dose and optimize clinical development.